Cyllene Therapeutics secured a $37 million Series C to advance EG110A through late-stage clinical development for severe neurogenic bladder. The financing signals continued investor appetite for gene therapy in urology where durable symptom control and reduced dependency on chronic interventions remain key clinical goals. The company’s lead program is positioned for progression to later studies, with the funding intended to support manufacturing, clinical execution, and regulatory preparation. For biotech developers, it adds to the broader pattern of capital flowing to modality-focused platforms where clinical readouts can de-risk both efficacy and scalability. As gene therapy investors evaluate durability and safety in chronic indications, CYllene’s Series C provides a concrete checkpoint: late-stage movement rather than platform-only proof.